{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:37Z","timestamp":1790837197203,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP20K16078"],"award-info":[{"award-number":["JP20K16078"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00280-020-04178-x","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T05:03:07Z","timestamp":1603429387000},"page":"803-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma"],"prefix":"10.1007","volume":"86","author":[{"given":"Kojiro","family":"Hata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Suetsugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3673-6824","authenticated-orcid":false,"given":"Nobuaki","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Makihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatake","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Kohjima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satohiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"issue":"3","key":"4178_CR1","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.ccr-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS (2019) The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res 25(3):912\u2013920. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-1254","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4178_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"1","key":"4178_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. https:\/\/doi.org\/10.1016\/s1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"issue":"28","key":"4178_CR4","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/jco.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park J-W, Poon RTP, Raoul J-L, Philip PA, Hsu C-H, Hu T-H, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han K-H, Paik S-W, Robles-Avi\u00f1a J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak W-Y, Jeng L-B, Liu D, Ezzeddine R, Walters I, Cheng A-L (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31(28):3517\u20133524. https:\/\/doi.org\/10.1200\/jco.2012.48.4410","journal-title":"J Clin Oncol"},{"issue":"32","key":"4178_CR5","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/jco.2012.45.8372","volume":"31","author":"A-L Cheng","year":"2013","unstructured":"Cheng A-L, Kang Y-K, Lin D-Y, Park J-W, Kudo M, Qin S, Chung H-C, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31(32):4067\u20134075. https:\/\/doi.org\/10.1200\/jco.2012.45.8372","journal-title":"J Clin Oncol"},{"issue":"2","key":"4178_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/jco.2013.54.3298","volume":"33","author":"C Cainap","year":"2015","unstructured":"Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, Kudo M, Kang Y-K, Chen P-J, Toh H-C, Gorbunova V, Eskens FALM, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S (2015) Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33(2):172\u2013179. https:\/\/doi.org\/10.1200\/jco.2013.54.3298","journal-title":"J Clin Oncol"},{"issue":"10064","key":"4178_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"4178_CR8","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. https:\/\/doi.org\/10.1155\/2014\/638747","journal-title":"J Thyroid Res"},{"issue":"1","key":"4178_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/0008-5472.can-17-2291","volume":"78","author":"LJ Wilson","year":"2018","unstructured":"Wilson LJ, Linley A, Hammond DE, Hood FE, Coulson JM, Macewan DJ, Ross SJ, Slupsky JR, Smith PD, Eyers PA, Prior IA (2018) New perspectives, opportunities, and challenges in exploring the human protein kinome. Can Res 78(1):15\u201329. https:\/\/doi.org\/10.1158\/0008-5472.can-17-2291","journal-title":"Can Res"},{"issue":"10126","key":"4178_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, Baron A, Park J-W, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng A-L (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 391(10126):1163\u20131173. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1","journal-title":"The Lancet"},{"issue":"5","key":"4178_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102(5):765\u2013776. https:\/\/doi.org\/10.1002\/cpt.787","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"4178_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111(10):1909\u20131916. https:\/\/doi.org\/10.1038\/bjc.2014.503","journal-title":"Br J Cancer"},{"issue":"5","key":"4178_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/bcp.12550","volume":"79","author":"H Yu","year":"2015","unstructured":"Yu H, Steeghs N, Kloth JSL, De Wit D, Van Hasselt JGC, Van Erp NP, Beijnen JH, Schellens JHM, Mathijssen RHJ, Huitema ADR (2015) Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol 79(5):809\u2013819. https:\/\/doi.org\/10.1111\/bcp.12550","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4178_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcph.73","volume":"53","author":"BI Rini","year":"2013","unstructured":"Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ (2013) Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53(5):491\u2013504. https:\/\/doi.org\/10.1002\/jcph.73","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4178_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","volume":"13","author":"S Noda","year":"2015","unstructured":"Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13(4):350\u2013358. https:\/\/doi.org\/10.1016\/j.clgc.2015.01.007","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"4178_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12032-018-1113-8","volume":"35","author":"R Igarashi","year":"2018","unstructured":"Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T (2018) Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Med Oncol 35(4):51. https:\/\/doi.org\/10.1007\/s12032-018-1113-8","journal-title":"Med Oncol"},{"issue":"3","key":"4178_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11523-014-0349-2","volume":"10","author":"YL Teo","year":"2015","unstructured":"Teo YL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2015) Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol 10(3):429\u2013437. https:\/\/doi.org\/10.1007\/s11523-014-0349-2","journal-title":"Target Oncol"},{"issue":"5","key":"4178_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","volume":"36","author":"M Nagahama","year":"2019","unstructured":"Nagahama M, Ozeki T, Suzuki A, Sugino K, Niioka T, Ito K, Miura M (2019) Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol 36(5):39. https:\/\/doi.org\/10.1007\/s12032-019-1263-3","journal-title":"Med Oncol"},{"issue":"4","key":"4178_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H (2017) Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52(4):512\u2013519. https:\/\/doi.org\/10.1007\/s00535-016-1263-4","journal-title":"J Gastroenterol"},{"issue":"9","key":"4178_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jcph.917","volume":"57","author":"T Tamai","year":"2017","unstructured":"Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, Kumada H (2017) Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol 57(9):1138\u20131147. https:\/\/doi.org\/10.1002\/jcph.917","journal-title":"J Clin Pharmacol"},{"key":"4178_CR21","unstructured":"Pharmaceuticals and Medical Devices Agency (2018) Lenvima Review Reports. https:\/\/www.pmda.go.jp\/files\/000233542.pdf. Accessed 19 June 2020"},{"issue":"7","key":"4178_CR22","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/annonc\/mdv189","volume":"26","author":"E Funck-Brentano","year":"2015","unstructured":"Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Funck-Brentano C, Saiag P (2015) Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Ann Oncol 26(7):1470\u20131475. https:\/\/doi.org\/10.1093\/annonc\/mdv189","journal-title":"Ann Oncol"},{"key":"4178_CR23","unstructured":"Food and Drug Administration (2014) Center for Drug Evaluation and Research Lenvatinib Clinical Pharmacology and Biopharmaceutics Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206947Orig1s000ClinPharmR.pdf. Accessed 19 June 2020"},{"issue":"8","key":"4178_CR24","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/cam4.2241","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, Real-life Practice Experts for Hcc Study Group HCCG (2019) Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis. Cancer Med 8(8):3719\u20133728. https:\/\/doi.org\/10.1002\/cam4.2241","journal-title":"Cancer Med"},{"key":"4178_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111769","author":"R Sasaki","year":"2019","unstructured":"Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K (2019) Response to lenvatinib is associated with optimal relativedose intensity in hepatocellular carcinoma: experience in clinical settings. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11111769","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4178_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000479984","volume":"6","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M (2017) Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 6(4):325\u2013336. https:\/\/doi.org\/10.1159\/000479984","journal-title":"Liver Cancer"},{"issue":"4","key":"4178_CR27","doi-asserted-by":"publisher","first-page":"e0231427","DOI":"10.1371\/journal.pone.0231427","volume":"15","author":"A Fuchigami","year":"2020","unstructured":"Fuchigami A, Imai Y, Uchida Y, Uchiya H, Fujii Y, Nakazawa M, Ando S, Sugawara K, Nakayama N, Tomiya T, Mochida S (2020) Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. PLoS ONE 15(4):e0231427. https:\/\/doi.org\/10.1371\/journal.pone.0231427","journal-title":"PLoS ONE"},{"issue":"3","key":"4178_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","volume":"93","author":"LJ Havrilesky","year":"2015","unstructured":"Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J (2015) A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol 93(3):203\u2013210. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"4178_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101517","author":"W Wang","year":"2019","unstructured":"Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N (2019) Sorafenib-regorafenib sequential therapy in japanese patients with unresectable hepatocellular carcinoma-relative dose intensity and post-regorafenib therapies in real world practice. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11101517","journal-title":"Cancers (Basel)"},{"key":"4178_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010049","author":"Y Eso","year":"2019","unstructured":"Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K, Seno H (2019) Dose intensity\/body surface area ratio is a novel marker useful for predicting response to lenvatinib against hepatocellular carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12010049","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4178_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357\u2013371. https:\/\/doi.org\/10.1007\/s00280-009-1170-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"4178_CR32","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/jco.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 27(19):3141\u20133147. https:\/\/doi.org\/10.1200\/jco.2008.20.4818","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04178-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T20:08:22Z","timestamp":1634933302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04178-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4178"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04178-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki and its amendments. The protocol was approved by the Institutional Review Board of the Ethics Committee of Kyushu University Graduate School and the Faculty of Medicine (Date November 27th, 2018\/No. 765-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in present study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}